Novel antidepressant-like properties of the fullerenol in an LPS-induced depressive mouse model. 2023

Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou 215006, People's Republic of China; Department of Military Cognitive Psychology, School of Psychology, Third Military Medical University (Army Medical University), Chongqing, People's Republic of China; Institute of Neuroscience, Soochow University, Suzhou 215123, People's Republic of China.

Depression is a common mental disease and is highly prevalent in populations. Dysregulated neuroinflammation and concomitant-activated microglia are involved in the pathogenesis of depression. Experimental evidence has indicated that fullerenol exerts anti-neuroinflammation and protective effects against neurological diseases. Here, we evaluated fullerenol's effects against lipopolysaccharide (LPS)-induced mouse depressive-like behaviors. Fullerenol treatment produced an antidepressant-like effect, as indicated by preventing the LPS-induced reduction in the sucrose preference and shortening the immobility durations in both the tail suspension test and the forced swim test. We found that fullerenol treatment mitigated LPS-induced hippocampal microglia activation and released proinflammatory cytokines. Meanwhile, fullerenol promoted hippocampus neurogenesis, evidenced by increased DCX-positive cells in LPS-treated mice. Hippocampal RNA-Seq analysis revealed proinflammatory cytokine and neurogenesis involved in fullerenol's antidepressant-like effects. Our data indicate that fullerenol exerts antidepressant effects, which might be due to beneficial functions in reducing neuroinflammatory processes and promoting neurogenesis in the hippocampus.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D013550 Swimming An activity in which the body is propelled through water by specific movement of the arms and/or the legs. Swimming as propulsion through water by the movement of limbs, tail, or fins of animals is often studied as a form of PHYSICAL EXERTION or endurance.
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
December 2021, Neuropharmacology,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
September 2022, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
August 2023, Neuropharmacology,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
October 2013, Progress in neuro-psychopharmacology & biological psychiatry,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
April 2022, Behavioural brain research,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
June 2018, Experimental neurobiology,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
May 2019, Molecules (Basel, Switzerland),
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
September 2022, BMC psychiatry,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
July 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Anqi Kong, and Tianyao Liu, and Shilong Deng, and Shiyao Xu, and Yi Luo, and Jianghui Li, and Zhulin Du, and Liuyongwei Wang, and Xingshun Xu, and Xiaotang Fan
January 2018, BioMed research international,
Copied contents to your clipboard!